Who
Indrani Lall Franchini
Director
Company insider
Files Form 4 as: Director, Avanos Medical; EVP, CLO & Secretary, Alnylam Pharmaceuticals; EVP, Chief Compliance Officer, Alexion Pharmaceuticals.
In numbers
- Trades disclosed
- 57
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $3.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 7 Jun 2017
- Last trade
- 27 Jul 2026
- Last filed
- 28 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 28 Jul 2026 | Avanos MedicalMedical Devices | SEC FORM 4 Code D | $120K4,817 at $25.00 | filing |
| 27 Jul 2026filed 28 Jul 2026 | Avanos Medicaloption or derivative · Medical Devices | SEC FORM 4 Code D | $300K12,003 at $25.00 | filing |
| 27 Jul 2026filed 28 Jul 2026 | Avanos Medicaloption or derivative · Medical Devices | SEC FORM 4 Code D | $300K12,003 at $25.00 | filing |
| 27 Jul 2026filed 28 Jul 2026 | Avanos MedicalMedical Devices | SEC FORM 4 Code D | $120K4,817 at $25.00 | filing |
| 8 May 2026filed 12 May 2026 | Avanos Medicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —12,003 at $0.00 | filing |
| 8 May 2026filed 12 May 2026 | Avanos Medicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —12,003 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | Avanos MedicalMedical Devices | SEC FORM 4 Code A | —12,003 at $0.00 | filing |
| 28 Feb 2024filed 29 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $22K142 at $154.54 | filing |
| 28 Feb 2024filed 29 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K111 at $155.45 | filing |
| 28 Feb 2024filed 29 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $10K66 at $156.38 | filing |
| 28 Feb 2024filed 29 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1,4169 at $157.30 | filing |
| 28 Feb 2024filed 29 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1581 at $158.09 | filing |
| 27 Feb 2024filed 29 Feb 2024 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —878 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —878 at $0.00 | filing |
| 2 Feb 2024filed 5 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $85K502 at $170.01 | filing |
| 2 Feb 2024filed 5 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $140K820 at $171.14 | filing |
| 2 Feb 2024filed 5 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $46K269 at $172.38 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,175 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —5,175 at $0.00 | filing |
| 6 Apr 2023filed 10 Apr 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $735K3,500 at $210.00 | filing |
News
Alnylam Pharmaceuticals, Inc.: Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseaseALNY · finanznachrichten.de · 23 Oct 2026Critical Survey: TScan Therapeutics (NASDAQ:TCRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · dailypolitical.com · 22 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonALNY · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Indrani Lall Franchini; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.